<!DOCTYPE html>
<html lang="en-US">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width initial-scale=1.0" />
    <title>VASCEPA (icosapent ethyl) - Impact of LDL-C</title>
    <meta name="description" content="Learn about why LDL-C is still an important consideration when treating patients with severe (≥500 mg/dL) hypertriglyceridemia.">
    <meta name="keywords" content="LDL-C, statin therapy, CVD risk, TG, randomized trials, Cholesterol Treatment Trialists’ (CTT) Collaboration">
    <link rel="stylesheet" type="text/css" href="../includes/style.css">
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.3/jquery.min.js"></script>
    <script src="../includes/main.js"></script>
    <script type="text/javascript">
        if(navigator.userAgent.match(/iPad/i)) {
            viewport = document.querySelector("meta[name=viewport]");
            viewport.setAttribute('content', 'width=960');
        }
    </script>
    <script src="//use.typekit.net/kfd3zyz.js"></script>
    <script>try{Typekit.load({ async: true });}catch(e){}</script>    <script>try{Typekit.load();}catch(e){}</script>
    <script>
        (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
        (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
        m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
        })(window,document,'script','//www.google-analytics.com/analytics.js','ga');
        ga('create', 'UA-60954107-1', 'auto');
        ga('send', 'pageview');
        
    </script>
    <script src="http://crypto-js.googlecode.com/svn/tags/3.1.2/build/rollups/sha1.js"></script>
    <script src="http://services.revhealthbackend.com/js/urlPassword.js"></script>
</head>

<body>
    <div id="wrapper">
        <div id="currentpg" data-current="managing"></div>
        <div id="top-child-content"></div>
        <div id="content" class="content-wrap">
            <div id="page-content">
                <div class="breadcrumbs">
                    <ul>
                        <a href="#">
                            <li class="current-page"><p>Impact of LDL-C</p></li>
                        </a>
                        <a href="epa-and-dha.html">
                            <li><p>EPA and DHA</p></li>
                        </a>
                        <a href="moa-of-epa.html">
                            <li><p>MOA of EPA</p></li>
                        </a>
                        <a href="epa-purity.html">
                            <li><p>EPA purity</p></li>
                        </a>
                        <a href="dietary-supplements.html">
                            <li><p>Dietary supplements</p></li>
                        </a>
                    </ul>
                </div>
                <div class="center-col">
                    <div class="page-text">
                        <h1>LDL-C is an important consideration in patients with VHTG<span style="text-transform: lowercase;">s</span><sup>1</sup></h1>
                        <p>Note that TGs are still in the primary target of therapy when levels are&nbsp;&ge;500 mg/dL.<sup>1</sup></p>
                        <p>Therefore, when adding a VHTG-lowering therapy to a statin, choosing a treatment that does not increase LDL-C is important.<sup>1</sup></p>
                        <p>A meta-analysis of 26 randomized trials* in 170,000 patients showed that further lowering LDL-C with statin therapy produced additional reductions in CVD risk.<sup>2</sup></p>
                        <p><span style="font-size: 12px;">*These trials included a total of 170,000 participants in statin trials and demonstrated that with each 1.0 mmol/L (39 mg/dL) reduction in LDL-C, the proportional annual risk of major vascular events was reduced by 22%. In other words, for each 1.8 mg/dL reduction in LDL-C with statin therapy, there is a 1% reduction in CVD risk.</span></p>
                        <p><span style="font-size: 12px;">CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; VHTG, very high triglyceride.</span></p>
                    </div>
                    <div class="load-child-disclaimer"></div>
                    <div class="references">
                        <strong>References: 1.</strong> Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia; part 1&ndash;executive summary. <em>J Clin Lipidol.</em> 2014;8(5):473-488. <strong>2.</strong> Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials. <em>Lancet.</em> 2010;376(9753):1670-1681.
                    </div>
                </div>
                <div class="page-sidebar">
                    <div class="load-child-callout"></div>
                    <div class="load-child-disclaimer"></div>
                </div>
            </div>
        </div>
        <div id="child-footer"></div>
    </div>
</body>
</html>